About UsNewsShop
Fighting hereditary breast and ovarian cancer
How to Help

Featured Research

For a listing of other research studies recruiting patients please visit our Active Studies page.

SOLO1 and SOLO2
SOLO1 and SOLO2

SOLO1 and SOLO2 are studies to determine if an investigational therapy, a PARP inhibitor, could be a successful treatment for women with BRCA-mutated ovarian cancer following chemotherapy.

NOVA Study
NOVA Study

A maintenance study investigating the PARP inhibitor niraparib for women with ovarian cancer who have high grade serous histology or known BRCA mutation and are platinum sensitive.

ARIEL 2
ARIEL 2

ARIEL2 is a new Phase 2 PARP inhibitor clinical trial now enrolling women with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.

FORCE Research Surveys
FORCE Research Surveys

FORCE conducts surveys to better understand and address the needs of our community. By participating, you can help advance hereditary breast and ovarian cancer research.

BRAVO
BRAVO

A study investigating the PARP inhibitor niraparib for women with previously treated HER2 negative, BRCA positive breast cancer.

BROCADE Study
BROCADE Study

A treatment study investigating the PARP inhibitor veliparib for people with advanced breast cancer who have a BRCA 1 or BRCA 2 mutation.

Salpingectomy Research Registry
Salpingectomy Research Registry

Study for women who have had their fallopian tubes surgically removed and kept one or both of your ovaries to reduce their ovarian cancer risk.

Basser Research Center for BRCA
Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center.

INFORM Study
INFORM Study

A study for newly-diagnosed breast cancer patients who carry a BRCA1 or BRCA2 mutation.

SOLO1 and SOLO2 SOLO1 and SOLO2

Women with BRCA-mutated cancer of the ovaries, peritoneum or fallopian tubes may be eligible for these studies. Women with unknown BRCA mutation status will be tested before starting treatment.

SOLO1 is for women with newly diagnosed ovarian cancer that has shrunk or disappeared following surgery and platinum-based chemotherapy.

SOLO2 is for women treated with at least two previous lines of platinum-based chemotherapy and their cancer shrunk or disappeared with the most recent line of therapy.

The information on this page is being provided with financial support from AstraZeneca.

More Information

NOVA Study NOVA Study

NOVA is a maintenance trial for women aged 18 and older with ovarian cancer to find out if niraparib (a PARP inhibitor) can help delay worsening of ovarian cancer among patients who had a good response to previous treatment with a platinum-type chemotherapy drug (i.e. cisplatin, carboplatin).  Niraparib will be compared to placebo and patients will be randomized so that 2 out of 3 patients will take niraparib and 1 out of 3 will take placebo.  This study is designed with the hope of preventing progression of the cancer after another treatment has caused the cancer to improve.

For more information visit:

www.tesarobio.com or http://clinicaltrials.gov/ct2/show/NCT01847274
 

More Information

ARIEL 2 ARIEL 2

ARIEL 2 is a new Phase 2 PARP inhibitor clinical trial now enrolling women with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. The primary goal of the study is to evaluate molecular markers to predict how a woman with ovarian cancer may respond to rucaparib treatment. All women enrolled in the study will receive rucaparib treatment and lab test results including BRCA and the molecular marker results.
 

More Information

FORCE Research Surveys FORCE Research Surveys

FORCE conducts surveys and partners with researchers who conduct surveys to better understand and address the needs of our community. By participating in surveys for which you are eligible, you help promote and advance hereditary breast and ovarian cancer research.

More Information

BRAVO BRAVO

BRAVO is a trial for men and women who have HER2 negative, BRCA mutation positive (hereditary) breast cancer that has progressed after previous treatment. The study will look at how well niraparib (a PARP inhibitor) works compared with standard chemotherapy. Patients will be randomized 2 to 1 so that two patients will take niraparib and one will take their doctor’s choice of chemotherapy. Collaborators for this international trial include the Breast International Group (BIG) and the European Organisation for Research and Treatment of Cancer (EORTC).

Visit clinicaltrials.gov at: http://clinicaltrials.gov/ct2/show/NCT01905592 or http://www.tesarobio.com


 

More Information

BROCADE Study BROCADE Study

Men and women aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation are invited to see if they may qualify for the Brocade Study to determine the safety and effectiveness of the investigational PARP inhibitor medication veliparib in combination with chemotherapy.

More Information

Salpingectomy Research Registry Salpingectomy Research Registry

Have you had your fallopian tubes surgically removed and kept one or both of your ovaries? Did you have this surgery to reduce your ovarian cancer risk? Researchers at the University of Washington in collaboration with Facing Our Risk of Cancer Empowered (FORCE) are studying the long-term outcomes of prophylactic salpingectomy (removal of the fallopian tubes). To learn more about this research study, call 206-685-7927 or email vhy@uw.edu orkagnew@uw.edu. They cannot ensure the confidentiality of any information sent by e-mail.

More Information

Basser Research Center for BRCA Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center. 

More Information

INFORM Study INFORM Study

INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited abnormality (mutation) in one of the breast cancer genes, BRCA1 or BRCA2. 

More Information


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org